Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Ophthalmic and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Serpin F1/PEDF drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Serpin F1/PEDF Recombinant Protein High purity (>95%), Endotoxin controlled (<1 EU/ug). Sequence Verified. HEK293 expressed for native glycosylation. |
View SERPINF1 Products |
| Gene Delivery | Serpin F1/PEDF Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View SERPINF1 Products |
| Benchmark Ab | Anti-Serpin F1/PEDF Recombinant Antibody Recombinant positive control for ELISA, Western Blot, and functional neutralization assays. |
View SERPINF1 Products |
| Validator | Serpin F1/PEDF siRNA Set For target knockdown verification in cell-based assays. |
View SERPINF1 Products |
| Related Target A | VEGFA The primary physiological antagonist of PEDF; critical for establishing the angiogenic index (PEDF/VEGF ratio) in ocular and tumor models. |
View VEGFA Products |
| Related Target B | PNPLA2 (PEDF-R) The high-affinity cell membrane receptor mediating PEDF-induced lipolysis and neuroprotective signaling pathways. |
View PNPLA2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Loss of native post-translational modifications affecting receptor binding | HEK293 mammalian expression host ensures native glycosylation patterns and correct folding. |
| Off-target interaction screening across the serpin superfamily | Sequence verified, high-purity recombinant proteins ensure minimal cross-contamination and accurate assay readouts. |
| Lack of reliable positive control antibodies | Sequence-defined clinical benchmark antibodies provide reproducible assay baselines. |
| Assay validation and target specificity confirmation | Pre-validated siRNA knockdown sets confirm sequence-specific target engagement. |
Live Serpin F1/PEDF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Serpin F1/PEDF therapeutics is expanding beyond traditional ophthalmology into oncology and metabolic disease indications. As a potent endogenous anti-angiogenic and neuroprotective factor, therapeutic strategies are shifting from simple recombinant protein replacement to advanced gene therapy vectors (e.g., AAV-mediated delivery) and peptide mimetics. The next wave of R&D focuses on maintaining localized, sustained therapeutic concentrations of PEDF to treat retinal degenerative diseases and solid tumors without systemic side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Genzyme, Academic Institutions | Wet AMD, Diabetic Macular Edema | Expression validation in target cells (Requires high-specificity anti-PEDF benchmark antibodies). |
| Peptide Therapeutics | Pharma Biotech Startups | Geographic Atrophy, Corneal Wound Healing | Receptor binding assays (Requires high-purity recombinant PNPLA2/PEDF-R and PLXDC2). |
| Recombinant Protein | Biotech R&D Centers | Metabolic Syndrome, Solid Tumors | Functional assay validation (Requires HEK293-expressed, endotoxin-controlled Serpin F1 protein). |